VYNE Therapeutics Inc.

VYNE Therapeutics Inc. reported a net loss of $26.5 million for fiscal year 2025, a significant improvement from a net loss of $39.8 million in 2024. Total revenues were minimal at $570K, while operating expenses totaled $30.3M, primarily driven by research and development ($19.2M) and general and administrative ($11.1M) costs. The company's cash position improved with cash and cash equivalents ending at $30.7M, supported by $37.4M in net cash provided by investing activities from marketable securities transactions. Key forward-looking developments include the discontinuation of the repibresib gel Phase 2b trial in July 2025 after it failed to meet primary and key secondary endpoints, and the pending merger with Yarrow which may impact the company's net operating loss carryforwards.

Key Takeaways